SS Innovations International Inc. (NASDAQ: SSII) has achieved a significant milestone with the launch of Sri Lanka's first robotic cardiac surgery program at Kings Hospital Colombo. The program utilizes the company's SSi Mantra 3.0 surgical robotic system, marking a new era in the country's cardiac care. This development not only showcases the clinical versatility of the SSi Mantra but also underscores SS Innovations' strategy to penetrate new markets and drive adoption of robotic-assisted surgery globally.
The inaugural procedure was a robotic-assisted left internal mammary artery (LIMA) takedown, performed by Dr. Sudhir Srivastava, founder and chairman of SS Innovations, alongside Kings Hospital cardiothoracic surgeon Dr. Rajitha DeSilva. This collaboration highlights the company's hands-on approach to supporting new programs and training local surgeons. According to a recent company video, Kings Hospital has already completed more than 25 robotic procedures in just three weeks, demonstrating rapid adoption and proficiency.
This launch is important because it signals the expanding global footprint of SS Innovations. As of the end of the second quarter, the company reported 224 cumulative SSi Mantra installations across 12 countries. The entry into Sri Lanka adds another country to that list and demonstrates the system's appeal in diverse healthcare environments. The successful start of a cardiac program is particularly noteworthy, as cardiac surgery is among the most complex surgical specialties, requiring precise instrumentation and experienced surgeons. The ability to perform robotic cardiac surgery effectively can serve as a proof point for the SSi Mantra's capabilities, potentially accelerating adoption in other countries and specialties.
Financially, the company's second-quarter revenue reached $13.9 million, while robotic procedures increased 143% year over year to 2,528. This sharp rise in procedure volume points to rising utilization of the company's installed base, which is a key metric for recurring revenue and long-term growth. As more hospitals adopt the SSi Mantra and surgeons gain experience, procedure volumes are likely to continue climbing, driving further revenue. The launch in Sri Lanka contributes to this momentum by adding a new center of excellence that can inspire other hospitals in the region.
Looking ahead, the next major corporate milestone is regulatory expansion. SS Innovations is pursuing U.S. FDA clearance and European CE marking for the SSi Mantra system. Achieving these certifications would open up two of the largest and most lucrative markets for surgical robotics, potentially transforming the company's growth trajectory. The successful deployment in Sri Lanka can support these regulatory efforts by providing clinical evidence and demonstrating the system's safety and efficacy in a real-world setting. Moreover, it strengthens the company's position as a global player in surgical robotics, capable of competing with established players.
For investors, the news is a reminder of SS Innovations' progress in executing its growth strategy. The company is not only expanding its installed base but also increasing utilization, which drives recurring revenue from instruments and services. The focus on regulatory approvals in the U.S. and Europe could be a catalyst for the stock, as these markets represent significant opportunities. However, investors should also note the risks associated with regulatory processes and competition. Nonetheless, the launch in Sri Lanka is a positive development that highlights the company's ability to innovate and expand globally. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
